ENTOD Pharma bags DCGI nod for Phase III trial of 0.05% Atropine eye drops
31 May 2022 | News
The company would be the first to launch the product in India subject to a successful demonstration of safety and efficacy
Image Credit: Shutterstock
ENTOD Pharmaceuticals has now got the approval to carry out phase 3 trials across India for their 0.05 per cent atropine eye drops from the Drugs Controller General of India (DCGI).
This higher strength of low-dose atropine eye drops is not available commercially anywhere in the world, and Mumbai-based ENTOD Pharmaceuticals would be the first company to launch this in India subject to a successful demonstration of safety and efficacy in clinical studies.
MYATRO 0.01 per cent eye drops are used to treat eye problems like myopia, especially in children when a child can see nearby objects but has problems seeing distant objects. Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children and has recently garnered a lot of interest from ophthalmologists.
